MOTS-c — Research Reference

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondria-derived peptide (MDP) consisting of 16 amino acids, encoded within the 12S ribosomal RNA gene of the mitochondrial genome. It was first characterised in 2015 by researchers at the University of Southern California and represents a relatively new class of signalling molecules — peptides produced by the mitochondria that act systemically to regulate metabolism and cellular stress responses.

Quick Reference

Overview

MOTS-c was identified as part of a broader effort to characterise bioactive peptides encoded in the mitochondrial genome — a small circular DNA distinct from nuclear DNA. Its discovery challenged the prevailing view that the mitochondrial genome exclusively encodes structural components of the respiratory chain.

Research has investigated MOTS-c for its potential role in:

• Insulin sensitivity and glucose regulation: Studies in rodent models have reported that MOTS-c administration improves insulin sensitivity and reduces diet-induced obesity and insulin resistance. Proposed mechanisms include AMPK pathway activation and modulation of the folate cycle.
• Metabolic homeostasis: MOTS-c is proposed to act as a systemic exercise-mimicking signal, with animal research reporting metabolic effects broadly similar to those of aerobic exercise — including improved mitochondrial function and enhanced fatty acid oxidation.
• Exercise performance: Rodent research has reported improvements in exercise capacity following MOTS-c administration. Human data in this area is limited.
• Healthy ageing: Plasma MOTS-c levels are reported to decline with age. Research has investigated whether restoring circulating MOTS-c may partially counteract age-related metabolic decline.
• Stress resistance: Cell and animal studies have reported that MOTS-c enhances cellular resistance to various metabolic stressors.

MOTS-c is not approved for human therapeutic use in any jurisdiction and is classified as a research compound. Human clinical trial data is limited at the time of writing.

Reported Protocols

The following information represents commonly reported research ranges drawn from anecdotal accounts. Clinical human dosing data is not established. These are not medical recommendations.

Subcutaneous Protocol

Subcutaneous injection is the most commonly reported administration route in anecdotal research accounts. Commonly reported doses range from 5 mg to 10 mg per week, administered in one or two injections.

• Frequency: Once or twice weekly injections are the most commonly described approach
• Duration: Commonly reported research periods of 4–12 weeks, often followed by an off period of similar length
• Exercise context: Some anecdotal research accounts describe administration pre-exercise based on the proposed exercise-mimicking mechanism, though optimal timing has not been established in human research

Intramuscular Protocol

Intramuscular injection is also reported in research contexts, with dosing similar to the subcutaneous protocol.

Reported Effects

The following effects have been reported in preclinical research and anecdotal accounts. This list reflects the research landscape, not confirmed clinical outcomes.

Insulin Sensitivity

The most extensively studied area in published MOTS-c research concerns insulin sensitivity. Rodent studies have reported improved glucose tolerance and reduced insulin resistance following MOTS-c administration in high-fat diet models, with researchers proposing AMPK activation and folate cycle modulation as contributing mechanisms.

Mitochondrial Function

Research has investigated MOTS-c for its potential role in improving mitochondrial efficiency and biogenesis — processes associated with improved energy metabolism and reduced oxidative stress. Anecdotal reports in research contexts describe improved energy levels and exercise recovery.

Exercise Performance and Body Composition

Animal research has reported enhanced exercise capacity and shifts in body composition (reduced fat mass, preserved lean mass) following MOTS-c administration. Anecdotal human research accounts describe similar effects, though these reports are preliminary and uncontrolled.

Anti-ageing Mechanisms

Research has investigated MOTS-c in the context of age-related metabolic decline. The age-associated decrease in circulating MOTS-c has led researchers to propose it as a potential target for longevity interventions, though this remains highly speculative.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

MOTS-c is a relatively newly characterised compound. Long-term safety data in humans is absent, and the anecdotal research base is smaller than for older, more established peptides. The compound has not undergone comprehensive human safety trials.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Room temperature: Reported stable for up to 3 months when kept away from light and moisture
• Refrigerator (2–8°C): Preferred for extended storage; protect from light
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles
• Light sensitivity: Store in an opaque or amber vial; avoid direct light exposure

Reconstituted Solution

• Refrigerator (2–8°C): Use within 4–6 weeks of reconstitution
• Do not freeze a reconstituted solution
• Bacteriostatic water (BAC water) is the standard diluent for multi-use vials
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

Add bacteriostatic water slowly along the inside wall of the vial. Swirl gently — do not shake. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

What makes MOTS-c different from other longevity peptides? MOTS-c is unique in that it is encoded by the mitochondrial genome rather than the nuclear genome — the first peptide identified from this source to act as a systemic hormone. This positions it within a newly described class called mitochondria-derived peptides (MDPs). Its proposed mechanism, involving metabolic regulation via AMPK and the folate cycle, differs from the mechanisms of other commonly researched longevity compounds such as Epitalon or GHK-Cu.

Is there human trial data on MOTS-c? Human clinical trial data on MOTS-c is limited as of this writing. The majority of the published research base consists of cell and rodent studies. Anecdotal human reports exist in research communities but are not controlled and should be interpreted with appropriate caution.

What is the proposed connection to exercise? Rodent research has reported that MOTS-c levels rise in muscle tissue during exercise and that exogenous MOTS-c administration produces metabolic effects broadly similar to aerobic training — including improved insulin sensitivity and mitochondrial function. Researchers have described MOTS-c as a candidate “exercise hormone,” though this characterisation remains speculative.

How does MOTS-c relate to NAD+ research? Both MOTS-c and NAD+ are areas of research interest in the context of mitochondrial function and metabolic ageing. They act through distinct mechanisms — NAD+ as a coenzyme central to cellular energy metabolism and sirtuin activation, MOTS-c as a signalling peptide modulating AMPK and glucose metabolism. They are sometimes researched together in longevity-focused protocols.

Related Pages

Goals: Longevity · Metabolic Health · Performance

Class: Mitochondrial Peptides

Comparisons: Epitalon vs MOTS-c

References & Further Reading

• Lee C, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454. PubMed →
• Kim KH, et al. (2018). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 10, 470. PubMed →
• Reynolds JC, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Aging, 1, 972–986. PubMed →